Author claims MREO is cheap at ~$0.70 with cash runway to mid-2027, no big debt, another drug in the works, and analyst upside around 3x.
MREO — LONG The author argues MREO is cheap at about $0.70 after being wrecked but climbing, supported by cash lasting to mid-2027, no big debt, and another drug in the works. The mechanism is a low valuation relative to analyst targets around 3x, with the catalyst being continued pipeline progress. The main stated risk is framed as gambling on the stock.
MREO’s is cheap at about .70. It got wrecked but keeps climbing. Cash lasts to mid-2027, no big debt, another drug in the works, and analysts have it around 3x.